Hakeem Health’s $1.65m round puts HakeemDx in GCC hospital AI procurement race

Hakeem Health raised $1.65 million to expand HakeemDx across GCC hospitals, giving CIOs, CFOs and medical directors a clinical AI vendor to evaluate before 2026 budgets close.

The round, announced by WAYA on 10 May 2026, was led by Merak Capital with participation from Sanabil 500. Hakeem Health is building HakeemDx, a bilingual Arabic-English clinical decision support platform that connects to electronic medical records and laboratory systems. For UAE operators, the near-term question is who pays for integration, who approves clinical content, and how evidence is logged for Dubai Health Authority (DHA), Department of Health Abu Dhabi (DOH) and Ministry of Health and Prevention (MOHAP) review.

What buyers need to price

HakeemDx is sold as SaaS for hospitals, universities and payers, according to Wamda. That makes the first buyer discussion a recurring operating expense, with the CIO, CFO, medical director and COO involved before a pilot reaches procurement.

• $1.65 million raised from Merak Capital and Sanabil 500.
• 2 named hospital system connections: EMR and laboratory platforms.
• 2 product languages: Arabic and English.
• More than 2,000 hospitals across Saudi Arabia, the UAE and Egypt are cited as the addressable regional base by WAYA.

Merak Capital is a Saudi investment firm managing more than SAR 3 billion across 10 funds, according to WAYA. Its lead role matters because an AI tool inside order entry, lab review or medication decisions carries a different risk profile from a patient chatbot.

Integration and accountability

The product claim that matters most for UAE hospitals is the EMR and lab connection. DHA-licensed facilities in Dubai, DOH-regulated providers in Abu Dhabi and Al Ain, and MOHAP-supervised providers in the Northern Emirates should treat any patient-specific AI assistant as an information governance project before go-live.

For medical directors, the core issue is accountability. Inc. Arabia reported that HakeemDx uses trusted medical guidelines, peer-reviewed research, drug information and clinical protocols before generating responses. That keeps the physician responsible for the decision, so hospitals need local policy on knowledge-base approval, review frequency, override documentation and incident escalation.

Our mission is to help clinicians make better decisions, faster, so patients receive better care.
Bilal Adi, founder and CEO, Hakeem Health

Bilal Adi and Mohammed Ayyad founded Hakeem Health in 2022, according to Inc. Arabia. The regional build matters in the UAE because clinical teams often work across Arabic, English, Urdu, Hindi and Tagalog, while hospital groups operate across more than one emirate.

What to watch in 2026

The first test is whether Hakeem Health can turn the $1.65 million round into signed institutional deployments during 2026. Hospitals should ask for evidence that HakeemDx reduces time to decision, lowers medication or diagnostic error risk, and fits inside existing EMR and laboratory workflows.

The second test is regulator fit. For DHA, DOH and MOHAP exposure, procurement teams should request integration references, model update logs, cybersecurity controls, data residency documentation and named responsibility for clinical content review before any hospital-wide rollout.

For UAE health tech founders and investors, the takeaway is concrete: capital is moving toward hospital infrastructure software again. The competitor to watch is HakeemDx, and the number to remember is 90 days, the period in which physicians usually decide whether a workflow tool helps or slows them down.